Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis.
Layer JP, Hamed M, Potthoff AL, Dejonckheere CS, Layer K, Sarria GR, Scafa D, Koch D, Köksal M, Kugel F, Grimmer M, Holz JA, Zeyen T, Friker LL, Borger V, Schmeel FC, Weller J, Hölzel M, Schäfer N, Garbe S, Forstbauer H, Giordano FA, Herrlinger U, Vatter H, Schneider M, Schmeel LC. Layer JP, et al. Among authors: forstbauer h. J Neurooncol. 2023 Aug;164(1):107-116. doi: 10.1007/s11060-023-04380-w. Epub 2023 Jul 21. J Neurooncol. 2023. PMID: 37477822 Free PMC article.
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial.
Bekes I, Eichler M, Singer S, Friedl TWP, Harbeck N, Rack B, Forstbauer H, Dannecker C, Huober J, Kiechle M, Lato K, Janni W, Fink V. Bekes I, et al. Among authors: forstbauer h. Clin Breast Cancer. 2020 Dec;20(6):439-447. doi: 10.1016/j.clbc.2020.03.008. Epub 2020 Apr 6. Clin Breast Cancer. 2020. PMID: 32800493 Clinical Trial.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Graeser M, Schrading S, Gluz O, Strobel K, Würstlein R, Kümmel S, Schumacher C, Grischke EM, Forstbauer H, Braun M, Christgen M, Adams J, Nitzsche H, Just M, Fischer HH, Aktas B, Potenberg J, von Schumann R, Kolberg-Liedtke C, Harbeck N, Kuhl CK, Nitz U. Graeser M, et al. Among authors: forstbauer h. Int J Cancer. 2021 May 15;148(10):2614-2627. doi: 10.1002/ijc.33495. Epub 2021 Feb 11. Int J Cancer. 2021. PMID: 33533487 Free PMC article.
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials.
Graeser M, Harbeck N, Gluz O, Würstlein R, Zu Eulenburg C, Schumacher C, Grischke EM, Forstbauer H, Dimpfl M, Braun M, Christgen M, Kreipe HH, Potenberg J, von Schumann R, Aktas B, Kolberg-Liedtke C, Kümmel S, Nitz U. Graeser M, et al. Among authors: forstbauer h. Breast. 2021 Oct;59:58-66. doi: 10.1016/j.breast.2021.06.001. Epub 2021 Jun 14. Breast. 2021. PMID: 34166854 Free PMC article.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C, Feuerhake F, Garke M, Christgen M, Kates R, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Graeser M, Nitz U, Kreipe H, Gluz O, Harbeck N. Kolberg-Liedtke C, et al. Among authors: forstbauer h. Breast Cancer Res. 2022 Sep 2;24(1):58. doi: 10.1186/s13058-022-01552-w. Breast Cancer Res. 2022. PMID: 36056374 Free PMC article. Clinical Trial.
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG). Eichhorst BF, et al. Blood. 2011 Feb 10;117(6):1817-21. doi: 10.1182/blood-2010-04-282228. Epub 2010 Dec 7. Blood. 2011. PMID: 21139079 Free article.
Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes.
Dejonckheere CS, Layer JP, Hamed M, Layer K, Glasmacher A, Friker LL, Potthoff AL, Zeyen T, Scafa D, Koch D, Garbe S, Holz JA, Kugel F, Grimmer M, Schmeel FC, Gielen GH, Forstbauer H, Vatter H, Herrlinger U, Giordano FA, Schneider M, Schmeel LC, Sarria GR. Dejonckheere CS, et al. Among authors: forstbauer h. J Neurooncol. 2023 Sep;164(3):683-691. doi: 10.1007/s11060-023-04464-7. Epub 2023 Oct 9. J Neurooncol. 2023. PMID: 37812290 Free PMC article.
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Jückstock J, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Heinrich G, Häberle L, Fasching PA, Beckmann MW, Coleman RE, Janni W, Rack B. Friedl TWP, et al. Among authors: forstbauer h. JAMA Oncol. 2021 Aug 1;7(8):1149-1157. doi: 10.1001/jamaoncol.2021.1854. JAMA Oncol. 2021. PMID: 34165508 Free PMC article. Clinical Trial.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; WSG-ADAPT investigators. Nitz U, et al. Among authors: forstbauer h. Lancet Oncol. 2022 May;23(5):625-635. doi: 10.1016/S1470-2045(22)00159-0. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405088 Clinical Trial.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer HH, Malter W, Hauptmann M, Kates RE, Gräser M, Würstlein R, Shak S, Baehner F, Kreipe HH, Harbeck N. Nitz UA, et al. Among authors: forstbauer h. J Clin Oncol. 2022 Aug 10;40(23):2557-2567. doi: 10.1200/JCO.21.02759. Epub 2022 Apr 11. J Clin Oncol. 2022. PMID: 35404683
50 results